SCHEMBL10105623

SCHEMBL10105623

Cc1nc(-n2cncn2)ccc1C(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP2A6 P11509 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE1C Q14123 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
KCNJ1 P48048 1/20 0.32
MAPT P10636 2/20 0.32
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
GLA P06280 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10105634 0.83 KDM4E (0.35) KDM4EPOLBALDH1A1SMN1; SMN2CYP2A6
SCHEMBL10120651 0.80 KDM4E (0.40) KDM4EPOLBALDH1A1SMN1; SMN2CYP2A6
SCHEMBL3372137 0.77 GRIN1 (0.39) KDM4EPOLBALDH1A1SMN1; SMN2CYP2A6
SCHEMBL1056459 0.77 KDM4E (0.39) KDM4EPOLBALDH1A1SMN1; SMN2CYP2A6
SCHEMBL26060647 0.74 KDM4E (0.43) KDM4EPOLBALDH1A1ADORA2AADORA1
SCHEMBL1823085 0.72 GABRP (0.46) KDM4EPOLBALDH1A1SMN1; SMN2MAPT
SCHEMBL11993146 0.71 SMN1; SMN2 (0.44) KDM4EALDH1A1SMN1; SMN2CYP2A6CYP1A2
Hydrochloric Acid SCHEMBL1822852 0.71 GABRP (0.45) KDM4EPOLBALDH1A1SMN1; SMN2MAPT
SCHEMBL354152 0.71 NNMT (0.45) KDM4EPOLBSMN1; SMN2CYP1A2CYP2C9
SCHEMBL1822851 0.71 KDM4E (0.40) KDM4EPOLBALDH1A1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822480-B2 Bicyclic heterocycle derivatives and use thereof as GPR119 modulators MERCK SHARP & DOHME CORP. (US) 2014-09-02 US disclosed
US-8815876-B2 Bicyclic heterocycle derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2014-08-26 US disclosed
US-20120040975-A1 BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2012-02-16 US disclosed
US-20120040975-A1 BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2012-02-16 US disclosed
US-20110166165-A1 BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS SCHERING CORPORATION (US) 2011-07-07 US disclosed
US-20110166167-A1 BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166165-A1 BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS GPR119, GPR88, GCGR KDM4E 3026/4885POLB 4654/4885ALDH1A1 1551/4885
US-20110166167-A1 BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GCGR, GLP1R KDM4E 3651/4885POLB 4470/4885ALDH1A1 1749/4885
US-20120040975-A1 BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF GPR119, BDKRB2, GLP1R KDM4E 3379/4885POLB 4285/4885ALDH1A1 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.